# Dyne Therapeutics Inc. (DYN) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $24.28, market value $4.5 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Dyne Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 5.7×**. The shares trade at 5.7× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -10.6%**. Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -45.9%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): -3.0%**. Earnings per share fell 3.0%.

## Financial health
- **Debt to equity: 0.15**. Debt is 0.15 times equity: a conservative balance sheet.

## Dividends
- **Dividend: none**. Dyne Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (15 analysts). 15 analysts cover Dyne Therapeutics Inc.; the consensus is strong_buy, with an average price target of $39.40 (+62% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 83.4%** (YTD 24.1%, 3-mo 42.5%). The shares are up 83.4% over twelve months including dividends.
- **From 52-week high: -11.1%** (103.7% above the low). Trading 11% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 40**. An RSI of 40 is neutral.
- **Beta (1 yr): 1.98** (volatility 77%). Beta of 1.98 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=DYN · Page: https://foliofundamentals.com/stocks/dyn

Not investment advice.